Nuveen
ENTA icon

Nuveen’s Enanta Pharmaceuticals ENTA Stock Holding History

Nuveen’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Buy
57,131
+4,861
+9% +$65.3K ﹤0.01% 3033
2026
Q1 		$660K Sell
52,270
-33,786
-39% -$453K ﹤0.01% 2744
2025
Q4 		$1.36M Sell
86,056
-78,704
-48% -$1,000K ﹤0.01% 2463
2025
Q3 		$1.97M Buy
164,760
+119,875
+267% +$958K ﹤0.01% 2302
2025
Q2 		$339K Sell
44,885
-11,786
-21% -$70.9K ﹤0.01% 3000
2025
Q1 		$313K Buy
56,671
+1,064
+2% +$6.57K ﹤0.01% 3029
2024
Q4 		$320K Hold
55,607
– – ﹤0.01% 3114
2024
Q3 		$576K Hold
55,607
– – ﹤0.01% 2964
2024
Q2 		$721K Sell
55,607
-33,780
-38% -$456K ﹤0.01% 2859
2024
Q1 		$1.56M Buy
89,387
+33,780
+61% +$447K ﹤0.01% 2506
2023
Q4 		$523K Buy
55,607
+106
+0.2% +$988 ﹤0.01% 2985
2023
Q3 		$620K Sell
55,501
-595
-1% -$9.58K ﹤0.01% 2770
2023
Q2 		$1.2M Hold
56,096
– – ﹤0.01% 2578
2023
Q1 		$2.27M Sell
56,096
-5,284
-9% -$252K ﹤0.01% 2281
2022
Q4 		$2.86M Sell
61,380
-9,095
-13% -$415K ﹤0.01% 2226
2022
Q3 		$3.66M Sell
70,475
-1,543
-2% -$90.1K ﹤0.01% 2077
2022
Q2 		$3.4M Sell
72,018
-73,462
-50% -$3.99M ﹤0.01% 2168
2022
Q1 		$9.67M Buy
145,480
+49,322
+51% +$3.21M ﹤0.01% 1662
2021
Q4 		$6.39M Buy
96,158
+14,612
+18% +$1.15M ﹤0.01% 1967
2021
Q3 		$4.76M Buy
81,546
+390
+0.5% +$19.3K ﹤0.01% 2242
2021
Q2 		$3.57M Sell
81,156
-3,863
-5% -$189K ﹤0.01% 2416
2021
Q1 		$4.19M Sell
85,019
-2,454
-3% -$122K ﹤0.01% 2246
2020
Q4 		$3.68M Sell
87,473
-3,114
-3% -$137K ﹤0.01% 2223
2020
Q3 		$4.15M Sell
90,587
-21,527
-19% -$1.04M ﹤0.01% 2021
2020
Q2 		$5.63M Buy
112,114
+13,282
+13% +$687K ﹤0.01% 1831
2020
Q1 		$5.08M Sell
98,832
-18,819
-16% -$1M ﹤0.01% 1707
2019
Q4 		$7.27M Sell
117,651
-92,118
-44% -$5.71M ﹤0.01% 1778
2019
Q3 		$12.6M Buy
209,769
+12,018
+6% +$893K 0.01% 1416
2019
Q2 		$16.7M Buy
+197,751
New +$17.8M 0.01% 1267

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's ENTA Position: Q2 2026 in Review

Nuveen increased its Enanta Pharmaceuticals (ENTA) stake by 9.3% in Q2 2026, buying an estimated $65.3K and bringing the position to 57,131 shares worth $833K. The position accounts for ﹤0.01% of the portfolio, ranked #3033.

Nuveen first reported a position in ENTA in Q2 2019 and has held it in 29 quarters since. The position peaked at $16.7M in Q2 2019. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Nuveen held 57,131 shares of Enanta Pharmaceuticals worth $833K as of Q2 2026.
  • Nuveen bought 4,861 Enanta Pharmaceuticals shares in Q2 2026, an estimated $65.3K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3033 holding.
  • Nuveen first reported a position in Enanta Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Enanta Pharmaceuticals position peaked at $16.7M in Q2 2019.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.